Analyst Coverage
Stock price graph

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Repros Therapeutics Inc.'s financial performance into perspective.

Recent Releases

Oct 5, 2016
Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities

Sep 26, 2016
FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

View all releases »

2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3446 fax